GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Central Pharmaceutical CPC1.JSC (HSTC:DP1) » Definitions » Debt-to-EBITDA

Central Pharmaceutical CPC1.JSC (HSTC:DP1) Debt-to-EBITDA : 0.00 (As of . 20)


View and export this data going back to 2018. Start your Free Trial

What is Central Pharmaceutical CPC1.JSC Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Central Pharmaceutical CPC1.JSC's Short-Term Debt & Capital Lease Obligation for the quarter that ended in . 20 was ₫0.00 Mil. Central Pharmaceutical CPC1.JSC's Long-Term Debt & Capital Lease Obligation for the quarter that ended in . 20 was ₫0.00 Mil. Central Pharmaceutical CPC1.JSC's annualized EBITDA for the quarter that ended in . 20 was ₫0.00 Mil.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Central Pharmaceutical CPC1.JSC's Debt-to-EBITDA or its related term are showing as below:

HSTC:DP1's Debt-to-EBITDA is not ranked *
in the Drug Manufacturers industry.
Industry Median: 1.7
* Ranked among companies with meaningful Debt-to-EBITDA only.

Central Pharmaceutical CPC1.JSC Debt-to-EBITDA Historical Data

The historical data trend for Central Pharmaceutical CPC1.JSC's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Central Pharmaceutical CPC1.JSC Debt-to-EBITDA Chart

Central Pharmaceutical CPC1.JSC Annual Data
Trend
Debt-to-EBITDA

Central Pharmaceutical CPC1.JSC Semi-Annual Data
Debt-to-EBITDA

Competitive Comparison of Central Pharmaceutical CPC1.JSC's Debt-to-EBITDA

For the Drug Manufacturers - Specialty & Generic subindustry, Central Pharmaceutical CPC1.JSC's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Central Pharmaceutical CPC1.JSC's Debt-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Central Pharmaceutical CPC1.JSC's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Central Pharmaceutical CPC1.JSC's Debt-to-EBITDA falls into.


;
;

Central Pharmaceutical CPC1.JSC Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Central Pharmaceutical CPC1.JSC's Debt-to-EBITDA for the fiscal year that ended in . 20 is calculated as

Central Pharmaceutical CPC1.JSC's annualized Debt-to-EBITDA for the quarter that ended in . 20 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is one times the quarterly (. 20) EBITDA data.


Central Pharmaceutical CPC1.JSC  (HSTC:DP1) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Central Pharmaceutical CPC1.JSC Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Central Pharmaceutical CPC1.JSC's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Central Pharmaceutical CPC1.JSC Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
No. 87 Nguyen Van Troi Street, Thanh Xuan, Hanoi, VNM
Central Pharmaceutical CPC1.JSC is engaged in the trading of Raw materials and auxiliary materials for the production of drugs, medical products, and pharmaceutical packaging. Some of its products include Bupivacaine Spinal Heavy 0.5%; Vitamin B Complex; Syntarpen 1g and others.

Central Pharmaceutical CPC1.JSC Headlines

No Headlines